)
Edge6 Mar 2026
Upvoted: The Story of Reddit
How Reddit built a unique platform around communities and conversation, turning human insight and intent into a distinctive business model.
NewAmsterdam Pharma Company
NewAmsterdam Pharma Company (NAMS) investor relations material
NewAmsterdam Pharma Company Leerink Global Healthcare Conference 2026 summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Leerink Global Healthcare Conference 2026 summary9 Mar, 2026
Recent clinical and regulatory progress
Completed phase III trials (BROOKLYN, BROADWAY, TANDEM) showing strong LDL-lowering efficacy and good tolerability for obicetrapib, with European approval filing underway this year.
BROADWAY mini outcome study (2,500 patients) demonstrated a 21% MACE benefit, supporting confidence in ongoing PREVAIL outcomes trial.
PREVAIL trial, with 9,500 patients, is designed to maximize success and is on track for completion, with minimum follow-up ending around November.
RUBENS diabetes trial aims to expand the label to include diabetic patients without heart disease, potentially increasing the eligible population by $20 million.
VINCENT trial is evaluating Lp(a) lowering in combination with a PCSK9 inhibitor.
Commercial outlook and partnerships
Anticipates European approval and commercial launch by Menarini, starting in Germany and the UK, with Europe expected to contribute 40-50% of global sales.
Royalty agreement ranges from low double digits to mid-20%, with expectations to reach 20%+ as sales milestones are met.
Approximately EUR 800 million in milestones remain, tied to approvals, launches, and sales thresholds.
Market opportunity is estimated at $8 billion or higher, with significant growth expected as treatment guidelines evolve.
Competitive landscape and differentiation
Obicetrapib offers oral administration, strong LDL and Lp(a) lowering, and favorable tolerability compared to injectables.
Positioned as a go-to therapy for patients with high Lp(a) and LDL, especially those not yet diagnosed with heart disease.
HORIZON trial outcomes for Novartis' Lp(a) agent seen as a win-win, with obicetrapib's benefits established regardless of HORIZON's results.
Merck's oral PCSK9 may launch first in the US, but obicetrapib will launch in Europe with outcome data in hand, offering additional benefits such as diabetes risk reduction and small particle elimination.
Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.Research faster. Power your platform.
Next NewAmsterdam Pharma Company earnings date
Q1 20266 May, 2026
NewAmsterdam Pharma Company
Next NewAmsterdam Pharma Company earnings date
Q1 20266 May, 2026
The essential earnings season companion
The #1 app for qualitative research. Live earnings calls, AI chat, transcripts, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
)
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
)
)
Frequently asked questions
NewAmsterdam Pharma Company N.V. is a clinical-stage biopharmaceutical company based in the Netherlands, focusing on the development of oral and non-statin medicines for patients at high risk of cardiovascular disease. Its leading product candidate is obicetrapib, a next-generation, oral, and low-dose cholesteryl ester transfer protein (CETP) inhibitor, currently in various stages of clinical trials. The company's mission is aimed at improving patient care in populations with metabolic diseases where currently approved therapies have not been sufficiently successful or well tolerated, with a significant focus on creating a potent, cost-effective, and convenient LDL-lowering therapy. The company is headquartered in Naarden, the Netherlands, and its shares are listed on the Nasdaq.
Quartr provides global coverage of all investor relation material from public companies.
Mobile app: Research anytime, anywhere with the #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Desktop (Quartr Pro): The leading platform for qualitative research, used daily by top firms and financial institutions.
Quartr API: Build custom solutions powered by live earnings calls, live transcripts, filings and reports, slide presentations, and more.
Yes, the Quartr mobile app is free on both iOS and Android.
Yes. Quartr provides global, industry-leading live coverage of company events such as regular earnings calls, capital markets days, M&A announcements, and investor conferences. Live with zero delays. Just click and listen.
Yes, capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Yes. Follow the companies that matter to you. Get a personalized feed with real-time updates, a tailored earnings calendar, and instant alerts when earnings calls go live.
Yes. Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned, regardless of who's talking.
Explore our global coverage